Guided Therapeutics Inc (GTHP)
OTHER OTC:GTHP
Total Valuation
Guided Therapeutics has a market cap or net worth of $23.10M. The enterprise value is $21.27M.
Market Cap$23.10M
Enterprise Value$21.27M
Share Statistics
Guided Therapeutics has 96,350,975 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding96,350,975
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Guided Therapeutics’s return on equity (ROE) is 0.53 and return on invested capital (ROIC) is 77.34%.
Return on Equity (ROE)0.53
Return on Assets (ROA)-2.41
Return on Invested Capital (ROIC)77.34%
Return on Capital Employed (ROCE)0.45
Revenue Per Employee191.75K
Profits Per Employee-799.00K
Employee Count4
Asset Turnover0.58
Inventory Turnover0.44
Valuation Ratios
The current PE Ratio of Guided Therapeutics is ―. Guided Therapeutics’s PEG ratio is 1.15.
PE Ratio―
PS Ratio55.21
PB Ratio-7.05
Price to Fair Value-7.05
Price to FCF-39.57
Price to Operating Cash Flow-17.61
PEG Ratio1.15
Income Statement
In the last 12 months, Guided Therapeutics had revenue of 767.00K and earned -3.20M in profits. Earnings per share was -0.04.
Revenue767.00K
Gross Profit571.00K
Operating Income-2.37M
Pretax Income-3.20M
Net Income-3.20M
EBITDA-2.47M
Earnings Per Share (EPS)-0.04
Cash Flow
In the last 12 months, operating cash flow was -1.07M and capital expenditures -2.00K, giving a free cash flow of -1.07M billion.
Operating Cash Flow-1.07M
Free Cash Flow-1.07M
Free Cash Flow per Share-0.01
Dividends & Yields
Guided Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.07
52-Week Price Change139.00%
50-Day Moving Average0.33
200-Day Moving Average0.29
Relative Strength Index (RSI)45.36
Average Volume (3m)12.33K
Important Dates
Guided Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Guided Therapeutics as a current ratio of 0.09, with Debt / Equity ratio of -48.93%
Current Ratio0.09
Quick Ratio0.02
Debt to Market Cap0.05
Net Debt to EBITDA-1.16
Interest Coverage Ratio-3.84
Taxes
In the past 12 months, Guided Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate-0.05
Enterprise Valuation
Guided Therapeutics EV to EBITDA ratio is -18.29, with an EV/FCF ratio of -42.26.
EV to Sales58.96
EV to EBITDA-18.29
EV to Free Cash Flow-42.26
EV to Operating Cash Flow-42.34
Balance Sheet
Guided Therapeutics has $63.00K in cash and marketable securities with $2.94M in debt, giving a net cash position of -$2.88M billion.
Cash & Marketable Securities$63.00K
Total Debt$2.94M
Net Cash-$2.88M
Net Cash Per Share-$0.03
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 67.80%, with operating margin of -309.26%, and net profit margin of -416.69%.
Gross Margin67.80%
Operating Margin-309.26%
Pretax Margin-416.69%
Net Profit Margin-416.69%
EBITDA Margin-322.29%
EBIT Margin-336.25%
Analyst Forecast
The average price target for Guided Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―